Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Evidence backs surgery for BRCA1/2 women:

This article was originally published in Clinica

Executive Summary

Women with mutations in their BRCA1 and BRCA2 genes may be three times less likely to develop breast or ovarian cancer if they undergo surgery. In a prospective study of 170 patients, researchers found that the removal of the ovaries and fallopian tubes, or oophorectomy, was associated with a 75% decreased risk of subsequent breast or ovarian cancer. The study, by researchers from the Memorial Sloan-Kettering Cancer Center, in New York, appears in The New England Journal of Medicine (May 23).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066596

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel